Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- ESC 2026 Research Underscores the Burden of PSVT, Everest Medicines' CARDAMYST(R) Offers an Out-of-Hospital, Self-Administered Treatment OptionHONG KONG, Sept 21, 2026 - Everest Medicines announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients’ daily lives and quality of life in the periods between episodes. The findings are being presented in a moderated ePoster session titled “The Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes”. Everest Medicines acquired the rights to develop, manufacture, and commercialize CARDAMYST(R) (etripamil), a treatment for acute PSVT episodes, in Greater China (including Mainland China, Hong Kong, Macao and Taiwan) in March 2026. CARDAMYST(R) (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. CARDAMYST(R) is currently the only self-administered treatment for adults with PSVT to rapidly treat episodes. The drug was approved by the National Medical Products Administration (NMPA) of China in September 2026, for the conversion of acute symptomatic episodes of paroxysmal PSVT to sinus rhythm in adults. According to clinical data, treatment effects can be observed as early as five minutes after administration, with 64% of patients achieving conversion to sinus rhythm within 30 minutes and a median time to conversion of 17 minutes. CARDAMYST(R) was generally well tolerated, with predominantly mild adverse events, and significantly reduced the need for emergency department visits. Positioned as an on-demand treatment that enables patients to take control of their heart rhythm, CARDAMYST(R) empowers patients with PSVT to better manage their condition and their lives. It has the potential to transform the treatment paradigm for acute PSVT episodes from passive emergency care in hospitals to proactive self-management by patients, helping to alleviate anxiety during episodes, reduce emergency department visits and disease burden, and further improve long-term disease management and quality of life. Research presented at ESC Congress 2026 shows that PSVT is a chronic condition that continues to impact patients’ quality of life, rather than simply an occasional acute emergency. Patients with PSVT experience a substantial burden between episodes, with negative impacts on anxiety, daily activities, sleep, and work. Therefore, beyond acute treatment and subsequent catheter ablation, ensuring timely and convenient treatment during an episode is also an important aspect of PSVT management. For patients experiencing recurrent PSVT episodes, further data from studies of CARDAMYST(R) provide additional clinical support. The NODE-302 study evaluated patients with recurrent PSVT episodes during long-term follow-up. Across a total of 188 episodes, the overall conversion rate within 30 minutes was 60.2%, with a median time to conversion of 15.5 minutes and a cumulative conversion rate of 75.1% within 60 minutes. The conversion rate showed a numerical upward trend across multiple episodes. A patient’s response to the first episode was predictive of the response to subsequent episodes, with no evidence of diminished response with repeated use. In a patient-reported outcomes (PRO) analysis from the NODE-303 study, CARDAMYST(R) not only converted heart rhythm but also helped alleviate feelings of a racing or pounding heart and ease anxiety, with patients reporting sustained reductions from baseline in anxiety and stress related to future PSVT episodes. CARDAMYST(R) addresses the critical unmet need for acute self-treatment during PSVT episodes. By reducing the sense of losing control, it shifts the treatment focus from mere disease control to enhancing the overall patient experience. In December 2025, CARDAMYST(R) was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting PSVT to sinus rhythm in adults. CARDAMYST(R) is also in Phase III clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR), with positive Phase II results supporting its advancement. An estimated 3 to 6 million people in China are living with PSVT. Research presented at ESC Congress 2026 further highlights the quality-of-life burden experienced by patients between episodes, while CARDAMYST(R) offers an out-of-hospital, self-administered treatment option for acute episodes. As Everest Medicines’ first approved innovative therapy in the cardiovascular disease field, CARDAMYST(R) complements the Company’s existing portfolio and has the potential to benefit more than 12 million patients in China, including those with PSVT and atrial fibrillation with AFib-RVR.
- Zhonghong Medical Reports H1 2026 Net Profit Surge of Over 26-FoldZhonghong Pulin Medical Products Co., Ltd.
- AbbiskoAbbisko Therapeutics Announces Positive Preliminary Phase 2 Results with Lavengratinib (ABSK061) for the Treatment of Achondroplasia21 September 2026 (Beijing time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced positive preliminary efficacy results from the Phase II clinical study of lavengratinib (ABSK061), a selective...
- Antengene Corporation LimitedAntengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
- JACC: Clinical Electrophysiology veröffentlicht die 12-Monats-Ergebnisse der ersten Field PULSE-Studie am Menschen von Field Medical: 94,2 % PVI-Haltbarkeit pro Vene bei optimierter WellenformAktuelle HRX-Daten treiben den „Instantaneous Ablation"-Arbeitsablauf von Field Medical voran und erweitern die klinische Evidenz für Hochvolt-Fokal-PFA mit dem FieldForce™-PFA-System. ATLANTA und CARLSBAD, Kalifornien, 20. September 2026 -- Field Medical, Inc., ein...
- JACC: Clinical Electrophysiology publie les résultats à 12 mois du premier essai Field PULSE chez l'humain de Field Medical : 94,2 % de durabilité de l'isolement des veines pulmonaires, par veine, grâce à une forme d'onde optimiséeLes données de dernière minute présentées à HRX font progresser le protocole d'« ablation instantanée » de Field Medical et étoffent les données cliniques sur l'ablation focale par champ pulsé (PFA) à haute tension avec le système de PFA FieldForce™ ATLANTA et CARLSBAD, Californie, 20...
- StimCardio Medical Inc.StimCardio's NeuroPulse Study Reports Substantial Reduction in Recurrent Atrial Fibrillation Events Via Non-Invasive Wearable Neuromodulation Following Ablation90% freedom from atrial arrhythmias at six months with neuromodulation vs. 80.8% with sham Randomized, double-blind, sham-controlled results presented as late-breaking clinical science at HRX Live 2026 and simultaneously published in peer-reviewed Heart Rhythm ATLANTA and LOS ANGELES,...
- Field Medical, Inc.JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized WaveformLate-breaking HRX data advance Field Medical's "instantaneous ablation" workflow and expand the clinical evidence for high-voltage focal PFA with the FieldForce™ PFA System — Field Medical, Inc., advancing high-voltage focal...
- Beyond Review Volume: What Healthcare Payers Now Expect From Managed Care and Utilization Management ConsultingBHM Healthcare Solutions on what health plans now expect from managed care and healthcare payer consulting: results, not just advice.
- SodaPeak Launch 2026: Effective Formula For Men Health Supports Men's Virility and vitality. Read Soda Peak Gummies Supplement Facts & Ingredients Highlights.Soda Peak Gummies introduces a natural vitality formula for men, featuring SodaPeak with selected botanical ingredients, supplement facts, and a multi-ingredient blend designed for everyday men’s wellness and vitality support.
- Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous UrticariaResults support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study
- Yicai GlobalBioShanghai Week 2026 Opens -- Joining Forces to Build a Global Biopharmaceutical Innovation EcosystemA news report from Yicai Global: On September 17, the BioShanghai Week 2026 opened at Zhangjiang Science Hall in Shanghai. Themed "AI for Biopharma, Health for All," this year's event brings together innovation resources from around the world to...